AI Terminal
GENINCODE PLC
AGM Information • Jun 30, 2023
7669_dva_2023-06-30_926b434d-40bd-4ad9-a193-8ac351c59363.html
AGM Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 6154E
GENinCode PLC
30 June 2023
GENinCode Plc
("GENinCode" or the "Company")
Result of AGM
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
The voting results of the AGM were as follows:
| In Favour | Against | Withheld | |||
| Resolution | Votes | % | Votes | % | Votes |
| 1 | 46,388,742 | 99.99 | 2,846 | 0.01 | 0 |
| 2 | 34,651,559 | 96.80 | 1,145,210 | 3.20 | 10,594,819 |
| 3 | 46,382,742 | 99.99 | 2,846 | 0.01 | 6,000 |
| 4 | 46,382,742 | 99.99 | 2,846 | 0.01 | 6,000 |
| 5 | 46,382,742 | 99.99 | 2,846 | 0.01 | 6,000 |
| 6 | 46,382,742 | 99.99 | 2,846 | 0.01 | 6,000 |
| 7 | 45,246,378 | 97.54 | 1,139,210 | 2.46 | 6,000 |
| 8 | 46,382,742 | 99.99 | 2,846 | 0.01 | 6,000 |
| 9 | 46,382,742 | 99.99 | 2,846 | 0.01 | 6,000 |
| 10 | 45,252,378 | 97.54 | 1,139,210 | 2.46 | 0 |
| 11 | 46,388,742 | 99.99 | 2,846 | 0.01 | 0 |
| 12 | 46,388,742 | 99.99 | 2,846 | 0.01 | 0 |
| 13 | 45,252,378 | 97.54 | 1,139,210 | 2.46 | 0 |
| 14 | 45,252,378 | 97.54 | 1,139,210 | 2.46 | 0 |
A copy of the voting results can be found on the website later today here.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR | ||
| Matthew Walls, CEO | |||
| Paul Foulger, CFO | |||
| Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | ||
| Alex Price / Ben Maddison / Richard Short | |||
| Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | ||
| Giles Balleny | |||
| Dale Bellis / Michael Johnson (Sales) | |||
| Walbrook PR Limited Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage |
Tel: 020 7933 8780 or [email protected] | ||
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict the onset of cardiovascular disease.
About Cardiovascular Disease (CVD):
CVD is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.
CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas with the NHS 10 Year Plan identifying CVD as the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.
Early detection and treatment of CVD can help patients live longer, healthier lives. Too many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). The NHS 10 Year Plan is working towards people knowing and managing risks around their 'ABC' (AF, Blood pressure and Cholesterol).
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGBUGDLDGXDGXG